Print this page    •   Back to Web version of article

Medical News
Generic Drug Maker Receives FDA, PEPFAR Approval for Drug to Treat HIV-Positive Children

March 14, 2011

The generic drug maker Mylan Inc. on Thursday announced it has received final approval from the FDA under PEPFAR for a new formulation of the antiretroviral drug zidovudine that is specifically meant to treat children with HIV/AIDS, RTT News reports (3/10). The drug is a "first-of-its-kind" water-dispersible tablet that can also be used to prevent mother-to-child transmission of HIV, the Pittsburgh Business Times reports (Mamula, 3/10). "It will be made available for purchase outside the U.S. in certain developing countries," the Associated Press/Canadian Business Online reports (3/10). "The FDA's approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. The water-dispersible tablet is unique because it can be dispersed in water for all patients, adults or children, who are unable to swallow tablets," according to a Mylan press release (3/10).

Back to other news for March 2011


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.




This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art60998.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.